-
公开(公告)号：US20230033224A1
公开(公告)日：2023-02-02
申请号：US17758427
申请日：2021-01-06
摘要： The invention relates to ciclesonide or a pharmaceutically acceptable salt thereof or a composition comprising ciclesonide or a pharmaceutically acceptable salt thereof for the use in a method of ameliorating quality of life (QOL) in equines, preferably horses.
-
2.发明申请公开(公告)号：US20190008831A1
公开(公告)日：2019-01-10
申请号：US16027422
申请日：2018-07-05
发明人： Balazs ALBRECHT , Sven ANKE , Saskia KLEY , Stefan Johannes LEHNER , Marcus STARK , Anne Michelle TRAAS , Tanja Margrit ZIMMERING
IPC分类号： A61K31/4178 , A61P9/12 , A61K9/00
摘要： A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.
-
公开(公告)号：US20220378737A1
公开(公告)日：2022-12-01
申请号：US17873638
申请日：2022-07-26
发明人： Saskia KLEY , Dania REICHE
IPC分类号： A61K31/351 , A61K38/28 , A61K9/20 , A61K9/48 , A61K9/02 , A61K31/7034 , A61K45/06 , A61K9/08 , A61K31/00 , C07D309/10 , A61P5/50 , A61P27/12 , A61K47/22 , A61K31/352 , A61P9/12 , A61K9/14 , A61P3/00 , A61P3/06 , C07D493/08 , A61P3/10 , A61P3/04 , A61P31/12 , A61P29/00 , A61K9/00 , A61K31/401
摘要： One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably where the metabolic disorder is one or more selected from ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or musculoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or musculoskeletal disorders, is prevented or progression is slowed or remission is achieved.
-
4.发明申请公开(公告)号：US20210260090A1
公开(公告)日：2021-08-26
申请号：US17176285
申请日：2021-02-16
发明人： Carla KROH , Ingo Ulrich LANG , Horst ROSE , Franziska ROESSNER , Saskia KLEY
IPC分类号： A61K31/7034 , A61K31/7042 , A61K31/7048 , A61K31/7056 , A61K47/54 , A61K31/616 , A61K31/727 , A61K31/4184 , A61K31/341 , A61K31/585 , A61K31/138 , A61K31/4422 , A61K31/554 , A61K31/401 , A61K31/501 , A61P9/04
摘要： The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more cardiac diseases in feline animals
-
公开(公告)号：US20150164856A1
公开(公告)日：2015-06-18
申请号：US14573352
申请日：2014-12-17
发明人： Dania Birte REICHE , Silke HAAG-DIERGARTEN , Leah Jeanette HENNINGS , Saskia KLEY , Anne M. TRAAS
IPC分类号： A61K31/351 , A61K38/28
摘要： The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.
摘要翻译： 本发明涉及用于治疗和/或预防猫科动物代谢紊乱的一种或多种SGLT2抑制剂或其药学上可接受的形式，优选其中代谢紊乱是选自以下的一种或多种：酮症酸中毒 ，前期糖尿病，1型糖尿病或2型糖尿病，胰岛素抵抗，肥胖症，高血糖症，葡萄糖耐量降低，高胰岛素血症，血脂异常，血管兴奋素血症，亚临床炎症，全身炎症，低度全身炎症，肝脂质变性，动脉粥样硬化，胰腺炎症 ，神经病和/或综合征X（代谢综合征）和/或胰腺β细胞功能丧失和/或其中代谢紊乱的缓解，优选糖尿病缓解获得和/或维持。
-
6.发明公开公开(公告)号：US20240050456A1
公开(公告)日：2024-02-15
申请号：US18482334
申请日：2023-10-06
发明人： Carla KROH , Ingo Ulrich LANG , Horst ROSE , Franziska ROESSNER , Saskia KLEY
IPC分类号： A61K31/7034 , A61K47/54 , A61P9/04 , A61K31/138 , A61K31/341 , A61K31/401 , A61K31/4184 , A61K31/4422 , A61K31/501 , A61K31/554 , A61K31/585 , A61K31/616 , A61K31/7042 , A61K31/7048 , A61K31/7056 , A61K31/727
CPC分类号： A61K31/7034 , A61K47/545 , A61P9/04 , A61K31/138 , A61K31/341 , A61K31/401 , A61K31/4184 , A61K31/4422 , A61K31/501 , A61K31/554 , A61K31/585 , A61K31/616 , A61K31/7042 , A61K31/7048 , A61K31/7056 , A61K31/727
摘要： The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more cardiac diseases in feline animals.
-
公开(公告)号：US20230140631A1
公开(公告)日：2023-05-04
申请号：US18086830
申请日：2022-12-22
发明人： Dania Birte REICHE , Silke HAAG-DIERGARTEN , Leah Jeanette HENNINGS , Saskia KLEY , Anne M. TRAAS
IPC分类号： A61K31/351 , A61K38/28 , A61K31/7034 , C07D309/10 , C07H7/04 , A61P3/10 , A61K31/7042 , C07D493/10 , C07D493/08 , A61P3/06 , A61P31/12 , A61K31/357 , A61P9/12 , A61K31/381 , A61K31/7056 , C07H17/02 , C07D335/02 , A61K31/35 , A61K47/22 , C07D333/12 , A61P5/50 , A61P3/04 , C07H17/00 , C07H5/10 , A61P3/00 , C07H15/203 , A61P29/00 , C07D333/56
摘要： One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably where the metabolic disorder is one or more selected from the group consisting of ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or where the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.
-
8.发明申请公开(公告)号：US20210106564A1
公开(公告)日：2021-04-15
申请号：US17131312
申请日：2020-12-22
发明人： Balazs ALBRECHT , Sven ANKE , Saskia KLEY , Stefan Johannes LEHNER , Marcus STARK , Anne Michelle TRAAS , Tanja Margrit ZIMMERING
IPC分类号： A61K31/4178 , A61K9/00 , A61P9/12 , A61K31/4184
摘要： A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.
-
公开(公告)号：US20200179328A1
公开(公告)日：2020-06-11
申请号：US16790810
申请日：2020-02-14
发明人： Saskia KLEY , Dania REICHE
IPC分类号： A61K31/351 , A61K31/401 , A61K9/48 , A61K9/20 , A61K9/00 , A61K38/28 , A61K31/00 , A61K9/08 , A61K45/06 , A61K31/7034 , A61K9/02 , C07D309/10
摘要： The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.
-
公开(公告)号：US20160361289A1
公开(公告)日：2016-12-15
申请号：US15113127
申请日：2015-01-20
发明人： Saskia KLEY , Dania Birte REICHE
IPC分类号： A61K31/351 , A61K9/48 , A61K38/28 , A61K9/20 , A61K31/401 , A61K9/00
CPC分类号： A61K31/351 , A61K9/0053 , A61K9/02 , A61K9/08 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2059 , A61K9/4825 , A61K9/4858 , A61K9/4866 , A61K31/00 , A61K31/401 , A61K31/7034 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.
摘要翻译： 本发明涉及用于治疗和/或预防犬动物代谢紊乱的一种或多种SGLT2抑制剂或其药学上可接受的形式，优选其中所述代谢病症是选自以下的一种或多种：酮症酸中毒 ，糖尿病前期，胰岛素依赖性糖尿病，胰岛素抵抗糖尿病，胰岛素抵抗，肥胖症，高血糖症，高血糖诱导的白内障形成，葡萄糖耐量降低，高胰岛素血症，血脂异常，血管兴奋素血症，亚临床炎症，全身炎症，低度全身炎症，肝脂质沉积， 胰腺炎症，代谢紊乱后果如高血压，肾功能障碍和/或肌肉骨骼疾病和/或综合征X（代谢综合征），其中优选地，预防或发展高血糖诱导的白内障形成的发展和/或其中 最好是代谢紊乱的发展 如高血压，肾功能障碍和/或肌肉骨骼疾病等后遗症被阻止或进展缓慢或达到缓解。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.023 秒)
